Methods of antagonizing signal transduction in spinal cord cells
First Claim
Patent Images
1. A method of antagonizing signal transduction in spinal cord cells in a subject, comprising administering to the subject a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a first receptor consisting of amino acid residues 1-662 of SEQ ID NO:
- 8, or a second receptor consisting of amino acid residues 1-979 of SEQ ID NO;
16, or a heterodimeric receptor comprising the first and second receptors, and wherein after administration of the monoclonal antibody or antigen-binding fragment thereof, signal transduction through the heterodimeric receptor induced by a polypeptide comprising amino acid residues 27-164 of SEQ ID NO;
2 is reduced.
0 Assignments
0 Petitions
Accused Products
Abstract
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
-
Citations
5 Claims
-
1. A method of antagonizing signal transduction in spinal cord cells in a subject, comprising administering to the subject a monoclonal antibody or antigen-binding fragment thereof that specifically binds to a first receptor consisting of amino acid residues 1-662 of SEQ ID NO:
- 8, or a second receptor consisting of amino acid residues 1-979 of SEQ ID NO;
16, or a heterodimeric receptor comprising the first and second receptors, and wherein after administration of the monoclonal antibody or antigen-binding fragment thereof, signal transduction through the heterodimeric receptor induced by a polypeptide comprising amino acid residues 27-164 of SEQ ID NO;
2 is reduced. - View Dependent Claims (2, 3, 4, 5)
- 8, or a second receptor consisting of amino acid residues 1-979 of SEQ ID NO;
Specification